Localizing Epileptic Networks Using MRI and iEEG

Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Pennsylvania

About this trial

Upon successful completion of this study, the investigators expect the study's contribution to be the development of noninvasive imaging biomarkers to predict IEEG functional dynamics and epilepsy surgical outcomes. Findings from the present study may inform current and new therapies to map and alter seizure spread, and pave the way for less invasive, better- targeted, patient-specific interventions with improved surgical outcomes. This research is relevant to public health because over 20 million people worldwide suffer from focal drug-resistant epilepsy and are potential candidates for cure with epilepsy surgical interventions.

Eligibility criteria

Qualifiers

Patients with medication-refractory epilepsy

Planned intracranial EEG (IEEG) placement

Hypothesized to have temporal lobe epilepsy

Disqualifiers

Contraindication to 3T MRI (e.g. metal implants or claustrophobia), clinical features that typically preclude the use of IEEG (e.g. pregnancy), prior intracranial surgery or device, and IEEG findings that are non-diagnostic (e.g. seizure onset zone(s) not identified)

Trial design

Treatments tested in this trial

  • 3T Magnetic Resonance Imaging
  • Intracranial electroencephalography recordings
  • 7T Magnetic Resonance Imaging

Treatment groups

290 Participants
are divided into 1 treatment group

Sponsors and collaborators

University of Pennsylvania

Lead sponsor

Medical University of South Carolina

Collaborator